Semaglutide Reconstitution Calculator & Dosage Chart + Clinical Trial Protocols Guide

Semaglutide is the once-weekly GLP-1 drug behind Ozempic and Wegovy. It usually produces less weight loss than tirzepatide. Separate semaglutide trials measured fewer cardiovascular events in established cardiovascular disease, slower kidney decline in T2D with chronic kidney disease, and multi-year safety outcomes in defined diabetes and obesity cohorts. The evidence supports different doses for different jobs.

Moving from the 0.25 mg starter to 2.4 mg is nearly a tenfold increase, and higher doses produce more weight loss. Yet a single milligram value can serve different goals: 1.0 mg is a modest weight-loss dose but the proven kidney dose in type 2 diabetes. Dose selection therefore depends on the outcome and the tolerability cost of reaching it.

Semaglutide (Ozempic / Wegovy) Dosage Chart for Weight Loss

Higher semaglutide doses produce more effect. The dose ladder is a strength dial, although receptor adaptation changes how each step feels over time.

Across the ladder, receptor engagement rises about sixfold from the starter dose to the top, and weight loss rises with it. A single fresh receptor can produce near-maximum output at about 10% engagement, while a normal meal uses only 1% to 4% (receptor saturation).¹⁸ That snapshot does not describe what happens after continuous weekly exposure.

Weekly dosing keeps semaglutide at a steady level and gives the receptor little rest. Under constant exposure, receptors are pulled off the cell surface and become less responsive over time (receptor desensitization).¹⁸

Higher doses maintain more signal against that fade. This helps explain why appetite can return partly at a fixed dose and why each titration step can restore the effect.

A fresh receptor’s signal runs high and nearly flat across the dose range, while measured weight loss climbs. The chart separates that laboratory snapshot from the effect of sustained dosing.

The 0.25 mg starter is pharmacologically active. An early trial also measured weight loss at 0.05 mg daily, nominally about 0.35 mg per week, confirming activity in the low-dose zone without testing a weekly microdose protocol.¹³

The 2.4 mg maintenance dose sits on the shoulder of the effect curve rather than at a hard ceiling. The current adult weight-reduction label allows 7.2 mg after at least four weeks at 2.4 mg when additional loss is clinically indicated, and STEP UP measured more weight loss at 7.2 mg than at 2.4 mg.²³

Side effects rise along the same curve. Titration protocols therefore hold a dose until nausea and other gastrointestinal effects settle rather than escalating on a fixed target date.

Weight Loss: The Default Job

The pivotal obesity trial enrolled about 1,960 non-diabetic adults with a mean weight of 105 kg, BMI of 38, average age of 46, and a cohort that was roughly three-quarters women. At 2.4 mg weekly, average weight loss reached about 15% over 68 weeks.¹

Response varied widely: 86% lost at least 5%, 69% lost 10%, half lost 15%, and about one-third lost 20%.¹ These results describe that cohort rather than a universal forecast.

Semaglutide produced less weight loss than tirzepatide head-to-head, about 14% versus 20%.² Its body-composition substudy measured a roughly 62:38 fat-to-lean loss split by mass, compared with about 75:25 for tirzepatide in a separate trial.⁵

The scan overstates muscle loss because lean mass includes water and organ tissue. Lean mass rose as a share of total weight, and grip strength improved on semaglutide.¹⁸ Protein, resistance training, and strength trends provide more useful context than the scan ratio alone.

Wegovy and Ozempic Dose Schedule

The usual Wegovy weight-loss ladder is 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly. Each step normally holds at least 4 weeks, because a new dose takes about 4 to 5 weeks to reach full strength on semaglutide’s roughly 7-day half-life, and most of the drug clears over about 5 weeks after the last dose.⁷

The interval matters more than the size of the first step. A 2026 analysis comparing early trials with full escalation regimens found that the injected-semaglutide dose associated with nausea in half the exposed population rose from 2.5 to 6.4 mg per week; for vomiting it rose from 10.5 to 16.5 mg per week.

The confidence intervals overlapped, so the semaglutide-specific shift is directional rather than cleanly separated. Across the full incretin class, tolerance tracked escalation duration and number of steps, while the starting dose as a fraction of maintenance did not.²⁵

For adults who tolerate 2.4 mg for at least four weeks and need additional weight reduction, the current label allows a maximum of 7.2 mg weekly.²³

Ozempic uses a related diabetes ladder that ends at 2.0 mg weekly, a blood-sugar ceiling rather than the Wegovy obesity ceiling. Trial and label protocols hold the current step when nausea, vomiting, constipation, reflux, or food aversion has not settled. Most discontinuation occurs during titration rather than after a stable dose is established.¹

What Semaglutide Feels Like, Start to Plateau

The experience changes after each dose increase. Appetite suppression often arrives before weight loss, gastrointestinal effects peak after escalation, and both soften as the dose settles. These are patterns from real-world reports rather than trial incidence rates.

What does appetite suppression feel like on semaglutide?

The first change is often quieter food noise rather than a lower scale reading. The background pull toward snacks and the habit of planning the next meal can decline within days to two weeks, sometimes at the 0.25 mg starter. Smaller portions also feel filling sooner as stomach emptying slows.

Some appetite returns as each dose settles. A higher step can deepen suppression again, followed by another partial fade over several weeks. At maintenance, the effect is usually steadier and milder than the first-week change.

Returning food noise can reflect adaptation, but it does not justify escalating before gastrointestinal effects have resolved.

The side-effect arc, in felt terms

Nausea is front-loaded. It is often worst one or two days after an injection and during the week after each increase, then eases at a held dose.

Constipation can build more slowly and persist as stomach and intestinal movement slows. Sulfur burps, reflux, and prolonged fullness reflect the same delay. Fatigue clusters in the first weeks and during the fastest-loss period, when food intake is lowest.

Hair shedding several months into rapid loss is usually telogen effluvium, the temporary response seen after many large weight changes rather than direct drug toxicity. Facial volume loss is the same fat loss appearing earlier in older or leaner faces.

Some users also describe emotional flatness beyond food. The signal is widely reported but thinly studied.

Trials record what they pre-specify and what participants report, so they can miss symptoms that were not actively measured. Temperature changes, chills, hair shedding, sulfur burps, and low mood appear more often in user reports than in trial tables. Their absence from a label does not establish incidence or disprove the experience.

What to expect at each phase

The expectations that keep people on the drug

Weight loss is uneven. Water shifts can hold the scale flat for weeks while waist and clothing fit continue to change, especially around months two and three.

A plateau on a stable dose is an expected endpoint rather than proof that semaglutide has stopped working. Persistent hunger despite a tolerated dose suggests that the current drug or dose is not controlling appetite adequately.

Stopping removes the appetite signal while the underlying weight-regulation biology remains. Maintenance planning therefore begins before discontinuation rather than after regain starts.

The structural reason the good and the bad arrive together

Tirzepatide’s second receptor, GIP, buffers some nausea. Semaglutide has no comparable buffer, so its appetite and gastrointestinal effects rise through the same GLP-1 exposure.

In a maintenance trial, nausea affected 47% of participants during escalation but fell to 14% after the same 2.4 mg dose was held.⁴ Receptor exposure stayed constant; gastrointestinal tolerance changed. Restarting after missed doses can therefore recreate part of the escalation burden.

Skin dysesthesia is one signal that has since made it onto the label. The FDA added it to injectable semaglutide in January 2025, and it climbs the dose axis like everything else.¹⁹

Burning or tingling skin tracks the dose, not the weight lost, and an active-comparator study put the risk about twice that of another weight-loss drug — bupropion-naltrexone, whose users are also losing weight, which rules out the deficit as the cause.¹⁹ Semaglutide is informative here precisely because it is GLP-1-only: it carries the strongest version of this signal in the class while engaging no GIP or glucagon receptor, which locates the effect at the GLP-1 receptor rather than anywhere else. The working mechanism is selective amplification of ATP/P2X signaling on skin sensory nerves — a sensitization of existing pathways rather than new pain signaling, which fits a sensation that is unpleasant but usually mild. It is reversible, and it eases when the dose comes down.

Different Bodies See Different Doses

Fixed milligram dosing does not put the same drug level in every body. Body weight is the one covariate that meaningfully moves semaglutide exposure, and it moves it inversely: a lighter body sees more drug per milligram.

At the same dose, a 74 kg participant had about 1.4 times the exposure of a 110 kg reference, while a 143 kg participant had about 0.8 times.¹² Weight alone does not set the dose, but it helps explain why the trial mean transfers poorly to bodies outside the studied range.

Type 2 diabetes lowers weight loss by about one-third at the same dose: a diabetes trial produced about 10% loss at 2.4 mg versus 15% in non-diabetic obesity. Diabetes lowers exposure by about 15% and blunts the downstream response.¹⁰ ¹²

Lean, metabolically healthy users sit outside every efficacy trial. Higher exposure and a smaller fat reserve suggest greater side-effect and lean-mass risk, but no long-term trial has measured the outcome.

Routine care lands below the trial, too. In a real-world cohort, six-month semaglutide loss was about 8.8%, roughly 0.6 to 0.8 of the STEP figure, mostly through adherence and persistence rather than a weaker drug.¹⁵ Read the trial number as a ceiling to translate down toward your own body and your own consistency, not as a forecast.

Heart, Kidney, and Blood Sugar: Where the Record Lives

Semaglutide’s cardiovascular, kidney, blood-sugar, and weight evidence is attached to different doses and populations.

Cardiovascular risk evidence comes from a regimen that escalated toward 2.4 mg. In about 17,600 adults with overweight or obesity, established cardiovascular disease, and no diabetes, the primary cardiac composite occurred in 6.5% assigned to semaglutide and 8.0% assigned to placebo over roughly 40 months (HR 0.80, 95% CI 0.72–0.90).³ This is a secondary-prevention result in people who already had cardiovascular disease, not a fixed-dose comparison or a general heart-health claim.

Kidney protection evidence uses the 1.0 mg dose. In type 2 diabetes with chronic kidney disease, semaglutide slowed kidney-disease progression by about 24%.¹⁴ One milligram is a modest weight-loss dose but a proven kidney dose for that population.

Blood-sugar control approaches its ceiling below the weight-loss dose. The Ozempic ladder reaches 2.0 mg weekly, but doubling from 1.0 to 2.0 mg added only about 0.23 percentage points of HbA1c reduction and 0.9 kg of weight loss.¹¹ Beyond 1.0 mg, most of the added effect is on weight rather than glucose.

Coming Off and Maintenance

Semaglutide suppresses appetite but does not reset the biology that resists weight loss. A plateau forms when the lower intake meets the lower energy expenditure of a smaller body. Without a glucagon arm, semaglutide does not directly offset that decline.

Across GLP-1 trials, about 60% of lost weight returns within the first year and roughly 75% returns over the longer curve, with the fastest regain in the early months.²¹ The semaglutide extension follows the same direction.⁶ The pattern reflects removal of appetite suppression after major weight loss.

Continued treatment and full discontinuation produce different outcomes. The randomized withdrawal evidence compares continued 2.4 mg with stopping; it does not establish that reducing to 0.5 or 1.0 mg will hold the same plateau.⁴ One milligram has direct weight-loss evidence as an assigned treatment arm in type 2 diabetes, while small uncontrolled series suggest that dose reduction or reduced-frequency dosing can sometimes hold a plateau.¹⁰

No trial has established a Semaglutide step-down schedule. A lower-dose maintenance attempt is a practical translation supported by directional real-world evidence, not a trial-proven protocol.

Transition protocols use at least 1.2 g/kg/day of protein and progressive resistance training to protect strength as appetite returns. Practical tapers often hold each lower step for 8 to 12 weeks, although that schedule has not been tested directly.

Weight trajectory after restarting is also unstudied. Real-world data shows how often people restart, but not whether a second course reaches the same low point.

How Semaglutide Dosing and Reconstitution Are Calculated

Semaglutide dose selection comes before syringe math. The usual Wegovy weight-loss ladder is 0.25, 0.5, 1.0, 1.7, and 2.4 mg once weekly, with each step held for at least four weeks. Selected adults may increase to 7.2 mg after at least four weeks at 2.4 mg when additional weight reduction is clinically indicated.²³

The 0.25 mg dose is the starter rather than the maintenance target; the dosing sections above separate weight-loss, cardiovascular, kidney, blood-sugar, and maintenance goals before a target dose is chosen.

Branded Ozempic and Wegovy pens hide the math. Vial-based semaglutide is different: the vial holds a fixed number of milligrams, and the BAC water volume sets the concentration. The total drug does not change; only the draw volume does. Product access and compounding rules shift over time, so verify source, sterility, concentration, and current rules before any vial-based dosing under clinician supervision.¹⁶ ¹⁷

Concentration equals vial milligrams divided by BAC water milliliters. Divide the target dose by that concentration to get the draw volume; on a U-100 syringe, 1 mL equals 100 units:

Syringe units = (BAC water in mL × 100 ÷ vial amount in mg) × target dose in mg.

For example, a 10 mg vial mixed with 2 mL of BAC water is 5 mg/mL. A 0.25 mg dose draws 0.05 mL, or 5 units; a 1 mg dose draws 0.2 mL, or 20 units. Changing the water volume changes those syringe readings, not the milligram dose.

The per-vial BAC water and syringe-unit charts for the 2.5, 5, and 10 mg vials are below; the full mixing walkthrough lives on the reconstitution guide.

How to Reconstitute Semaglutide

Oral Semaglutide: Rybelsus Equivalence

Rybelsus is semaglutide taken by mouth with an absorption enhancer that carries it across the stomach lining (SNAC).¹² Oral absorption is low and variable. Label administration requires an empty stomach, no more than 4 oz of plain water, and a 30-minute wait before food, drink, or other oral medication.

The common shortcut "14 mg oral equals 1.0 mg injectable" runs too high. The supported steady-state bridge puts 14 mg oral daily closer to a 0.5 mg weekly injection.¹² The corpus does not validate a linear conversion beyond that anchor: 25 mg oral Wegovy has direct obesity-outcome data and a labeled oral titration, but it should not be translated into an injected milligram equivalent.

Switching routes is an exposure change, not a brand swap. A user moving from 14 mg Rybelsus to 1.0 mg Ozempic is stepping up, not matching.

FAQ

Related Topics

• Semaglutide Deep Dive — mechanism, outcomes, trial data, and side-effect depth
• Tirzepatide Dosing — the stronger weight-loss and body-composition comparator
• Retatrutide Dosing — investigational triple-agonist dosing
• GLP-1 Lean Mass — protein and resistance-training protocol
• Stopping GLP-1s — cross-compound stopping and maintenance framework
• Peptide Reconstitution Guide — all-peptide sterile handling and storage
• Peptide Reconstitution Calculator — calculator basics

References

¹ Wilding JPH, Batterham RL, et al. "Once-weekly semaglutide in adults with overweight or obesity." N Engl J Med. 2021. STEP 1 — the page uses the treatment-policy result, -14.9% at 68 weeks, because it includes discontinuation and rescue rather than describing only adherent completers. The 5/10/15/20% responder ladder was 86/69/51/32%. This is the reference body behind those numbers: n=1,961, no diabetes, mean 105 kg and BMI 37.9, 74% women, titrated to 2.4 mg on a light lifestyle program. It is also the maintenance-phase safety anchor, not a lean-user forecast.

² Aronne LJ, et al. "Tirzepatide versus semaglutide for obesity." N Engl J Med. 2025. SURMOUNT-5 — direct 72-week comparison in non-diabetic obesity, using the treatment-regimen estimand: -20.2% tirzepatide versus -13.7% semaglutide. This replaces an across-trial efficacy comparison for weight. It does not supply DXA body-composition data, so the page keeps that question in ref ⁵.

³ Lincoff AM, Brown-Frandsen K, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." N Engl J Med. 2023. SELECT — randomized escalation toward 2.4 mg in adults with overweight or obesity, established cardiovascular disease, and no diabetes; primary cardiovascular composite 6.5% vs 8.0% on placebo, HR 0.80 (95% CI 0.72–0.90). This supports the assigned regimen in that secondary-prevention cohort; it does not isolate 2.4 mg from the lower tolerated doses used during follow-up.

⁴ Rubino D, et al. STEP 4. JAMA. 2021. DOI 10.1001/jama.2021.3224 — all 902 participants first climbed the semaglutide ladder for 20 weeks; 803 who reached 2.4 mg were then randomized to continue or switch to placebo. Nausea was 46.8% during the open-label climb and 14.0% during the held-dose randomized phase, which is why escalation and maintenance rates are not interchangeable. Continuing produced -7.9% from randomization versus +6.9% after withdrawal. The design isolates continue-versus-stop; it does not test a lower-dose maintenance band.

⁵ Wilding JPH, et al. "Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study." J Endocr Soc. 2021;5(Suppl 1):A16-A17. DOI 10.1210/jendso/bvab048 — the 62:38 fat-to-lean split is a denominator derived from the reported DXA mass changes, not a ratio the abstract names. “Lean” includes water and organs, so the page does not relabel the 38% as muscle. Lean mass fell in kilograms while rising as a share of total mass; grip strength is carried separately in ref ¹⁸. The held primary is abstract-level, which limits any finer compartment claim.

⁶ Wilding JPH, et al. STEP 1 extension. Diabetes Obes Metab. 2022. DOI 10.1111/dom.14725 — treated completers regained 11.6 percentage points during the off-drug year, about two-thirds of their prior loss, and remained 5.6% below baseline at week 120. This is full discontinuation after trial treatment, not a randomized taper and not evidence that every user returns to baseline.

⁷ Semaglutide disposition — FDA Wegovy clinical-pharmacology review and prescribing information; Overgaard et al. 2019 population PK. Terminal half-life is about one week, so four to five half-lives are required for a new weekly dose to approach steady state. That is the clock behind the four-week hold and the roughly five-week washout language; it is not an observed “adaptation deadline.” FDA prescribing information; Dhillon review.

⁸ Gallbladder signal — the STEP semaglutide trials recorded gallbladder-related events in roughly 2.6% to 4.9%, with the highest rate in the intensive-lifestyle trial that also produced the largest loss. A randomized-trial meta-analysis found the class signal stronger in weight-loss trials, at higher doses, and with longer exposure. That pattern is why the page treats rapid loss and direct gallbladder-motility effects as joint contributors rather than assigning the entire signal to either one. JAMA Internal Medicine meta-analysis.

⁹ Rubino DM, et al. STEP 8. JAMA. 2022. DOI 10.1001/jama.2022.0470 — randomized active comparison in non-diabetic obesity: semaglutide 2.4 mg reached -15.8% versus -6.4% on liraglutide 3.0 mg at 68 weeks. This is used only for the liraglutide comparison; it does not replace STEP 1 as the placebo-controlled semaglutide anchor.

¹⁰ Davies M, et al. STEP 2. Lancet. 2021. DOI 10.1016/S0140-6736(21)00213-0 — assigned-dose comparison in overweight/obesity with T2D: about -7.0% at 1.0 mg and -9.6% at 2.4 mg, so 1.0 mg retained roughly 73% of the higher-dose mean effect in that cohort. The same 2.4 mg product produced about one-third less loss than STEP 1’s non-diabetic cohort. This is the lower-dose and T2D-attenuation instrument; it is not a post-loss step-down trial.

¹¹ Frías JP, et al. SUSTAIN FORTE. Lancet Diabetes Endocrinol. 2021. DOI 10.1016/S2213-8587(21)00174-1 — doubling 1.0 to 2.0 mg added 0.23 percentage points of HbA1c reduction and 0.93 kg in the trial-product analysis. The page uses this to separate endpoint curves: glucose is already near its shoulder above 1.0 mg even while weight can continue moving.

¹² Semaglutide exposure translation — the FDA obesity model uses 110 kg as reference: 74 kg gives 1.40× exposure (90% CI 1.38–1.43), while 143 kg gives 0.80×; sex, age, race, renal function, and injection site sit near 1.0. The T2D popPK independently places 55 kg about 40% above and 127 kg about 27% below an 85 kg reference. Oral 14 mg daily bridges to roughly 0.5 mg weekly injection exposure, not 1.0 mg, and oral variability is much larger because absorption is the bottleneck. FDA Wegovy and Rybelsus clinical-pharmacology reviews; Carlsson Petri 2018.

¹³ O’Neil PM, et al. Lancet. 2018. DOI 10.1016/S0140-6736(18)31773-2 — the only direct multi-dose semaglutide obesity instrument in the corpus: estimated loss rose from -6.0% at 0.05 mg/day to -13.8% at 0.4 mg/day with slow escalation, versus -2.3% placebo. The lowest arm totals about 0.35 mg/week and establishes low-exposure activity. Because it used daily injections, it does not validate a once-weekly 0.1–0.2 mg microdose schedule.

¹⁴ Perkovic V, et al. FLOW. N Engl J Med. 2024. Full text — 1.0 mg weekly in T2D with chronic kidney disease produced a primary kidney-outcome HR of 0.76. That makes 1.0 mg the directly measured renal-outcome dose for that phenotype; it does not make 1.0 mg a general kidney-prevention dose outside T2D plus CKD.

¹⁵ le Roux CW, et al. J Endocrinol Invest. 2026;49:413-423. DOI 10.1007/s40618-025-02792-1 — routine-care semaglutide arm n=1,393, adjusted -8.83% at six months. The achieved-dose distribution explains why this is used as a translation factor rather than a potency estimate: 79.9% started at 0.25 mg and 32.3% remained below 1.7 mg at month six. The cohort measures real-world dose and persistence together, not the isolated efficacy of 2.4 mg.

¹⁶ FDA. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." 2025. FDA statement

¹⁷ FDA. "FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from 503B bulks list." 2026. FDA statement

¹⁸ Semaglutide receptor-engagement model - PeptideFox semaglutide explainer, Chapter 6. Binding occupancy climbs about six-fold (roughly 7% to 42%) across the ladder and tracks the weight effect; a fresh receptor’s output saturates below about 10% surface engagement (Gao 2023), so its near-flat acute signal is a snapshot, not the dose-response. Under continuous weekly exposure the receptor desensitizes: semaglutide is a full beta-arrestin recruiter (GLP-1R Emax 106%, Coskun 2022 Table S2; corroborated by Oostdyk 2024) and downregulates surface GLP-1R within 12 hours at physiological albumin (Hinds 2024), so the sustained signal held against that fade, set by dose, is what carries the effect. Potency and PK anchors: Lau 2015 (cAMP EC50 6.2 pmol/L), Boianelli 2024 (free fraction 0.36%), FDA 2021 (weight-change EC50 54.6 nmol/L). Grip strength: Alissou M, Demangeat T, et al., SEMALEAN prospective real-world cohort, Diabetes Obes Metab. 2026;28:112-121, DOI 10.1111/dom.70141.

¹⁹ Dysesthesia/allodynia decision — STEP UP supplies the semaglutide dose gradient: 0.5% placebo, 6.0% at 2.4 mg, and 22.9% at 7.2 mg; FDA added dysesthesia to injectable labeling in January 2025. Frey et al. 2026 adds an active-comparator denominator: 35 versus 15 incident cases per 1,000 person-years against bupropion-naltrexone, adjusted HR 2.15 (1.57–2.96), in 20,504 weight-loss users. That makes weight loss alone a poor explanation. Frey is a preprint and the molecular mechanism remains unresolved, so the page carries the event and dose relationship without claiming a pathway.

²⁰ Thyroid signal — two different instruments land in the same direction: Bezin’s nationwide nested case-control study found adjusted HR 1.58 (1.27–1.95) after 1–3 years of GLP-1RA use; Silverii’s randomized-trial meta-analysis found thyroid-cancer OR 1.55 (1.05–2.27) with no overall-cancer signal. Bezin 2023; Silverii 2025. The convergence is why the page no longer says the human signal is absent. The absolute event base is small and neither instrument isolates semaglutide cleanly enough to estimate an individual rate, so the page does not convert the ratios into one.

²¹ Budini et al. GLP-1RA weight-regain meta-regression. eClinicalMedicine. 2026 — the fitted class curve approaches 75.3% regain of weight lost (95% CI 68.9–81.6), with rate constant 0.0302/week, half-life about 23 weeks, and roughly 60% returned by week 52. The page uses this for the shape of regain because it pools withdrawal instruments; ref ⁶ remains the semaglutide-specific one-year anchor.

²² Wang et al. GLP-1 weight-loss medications, depression, and suicidality. J Affect Disord. 2025;389:119670 — FAERS showed elevated semaglutide reporting for depression (ROR 1.87) and suicide/self-injury (ROR 1.73), but the same dataset’s completed-suicide and suicide-attempt terms ran below expected and the signal clustered in the 2023–2024 media surge. With no treated denominator or comorbidity adjustment, this can surface language worth asking about; it cannot supply incidence or establish causality. That internal contradiction is why the page carries the question without calling it a demonstrated harm.

²³ Higher-dose decision — the March 2026 Wegovy label keeps 2.4 mg as usual adult maintenance and permits 7.2 mg only after at least four tolerated weeks at 2.4 mg when more loss is needed. STEP UP directly compared 7.2 mg, 2.4 mg, and placebo over 72 weeks, so prospective evidence above 2.4 mg now exists; the longer cardiovascular, renal, and two-year safety instruments still sit at 2.4 mg or below. FDA prescribing information; Wharton et al..

²⁴ Garvey WT, et al. STEP 5. Nat Med. 2022;28:2083-2091. DOI 10.1038/s41591-022-02026-4 — separate 104-week randomized trial: -15.2% versus -2.6%, with the curve flattening around week 60 and holding through week 104. This is the on-drug durability instrument. It does not describe durability after withdrawal; refs ⁶ and ²¹ carry that question.

²⁵ Nauck MA, Punov V, Kang YM, Lim S. Diabetes Obes Metab. 2026;28:4232-4242. DOI 10.1111/dom.70613 — injected semaglutide’s nausea ED50 moved from 2.5 to 6.4 mg/week and vomiting ED50 from 10.5 to 16.5 mg/week between early- and full-escalation programs, but the phase-specific intervals overlap. Across nine incretin mimetics, escalation duration (r²=0.834; p=0.0010) and step count (r²=0.764; p=0.0045) tracked tolerance while starting fraction did not (p=0.093). The page therefore uses this for the decision to add time and steps, not as proof of a semaglutide-specific effect size.